Literature DB >> 11275002

Effect of simvastatin on vascular smooth muscle responsiveness: involvement of Ca(2+) homeostasis.

M Alvarez de Sotomayor1, C Pérez-Guerrero, M D Herrera, E Marhuenda.   

Abstract

This report is focused on the study of simvastatin-induced relaxation of rat aorta through its effects on vascular smooth muscle and Ca(2+) signalling. The presence of endothelium affected only the simvastatin-induced relaxation of aortic rings precontracted with noradrenaline, but not by depolarization with KCl 80 mM. Blockade of Ca(2+) entry through voltage-operated Ca(2+) channels (VOCCs) by diltiazem abolished the endothelium-dependent and direct relaxation, whereas Ca(2+)-ATPase inhibition by cyclopiazonic acid (3 x 10(-5) M) only affected the endothelium-dependent relaxation. In KCl-depolarised arteries concentration-response curves for CaCl(2) were shifted to the right in the presence of simvastatin (3 x 10(-6) and 3 x 10(-5) M) or diltiazem (10(-6) and 10(-7) M). The transient contraction caused by noradrenaline in Ca(2+)-free medium, which is mainly due to intracellular Ca(2+) release, was inhibited by simvastatin (3 x 10(-5) M) or cyclopiazonic acid (3 x 10(-5) M) and the contraction induced by CaCl(2) (2 x 10(-3) M) added after noradrenaline was inhibited by diltiazem and simvastatin. All the reported effects of simvastatin were inhibited by the product of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, mevalonate (10(-3) M). These findings demonstrate that the vascular effects of simvastatin may involve both Ca(2+) release from intracellular stores, which could promote activation of endothelial factors, and blockade of extracellular Ca(2+) entry, which promote relaxations independent of the presence of endothelium. This action on Ca(2+) could be related to the inhibition of isoprenoid synthesis, which subsequently affects the function of G-proteins involved in communication among intracellular Ca(2+) pools and capacitative Ca(2+) entry.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11275002     DOI: 10.1016/s0014-2999(01)00819-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide.

Authors:  Cristine Skogastierna; Leonid Luksha; Karolina Kublickiene; Erik Eliasson; Anders Rane; Lena Ekström
Journal:  Heart Vessels       Date:  2011-01-07       Impact factor: 2.037

2.  Modulation by simvastatin of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine coronary artery smooth muscle cells.

Authors:  S W Seto; A L S Au; T Y Lam; S S C Chim; S M Y Lee; S Wan; D C S Tjiu; N Shigemura; A P C Yim; S W Chan; S K W Tsui; G P H Leung; Y W Kwan
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

3.  Effects of simvastatin on cardiohemodynamic responses to ischemia-reperfusion in isolated rat hearts.

Authors:  Xia Zheng; Shen-Jiang Hu
Journal:  Heart Vessels       Date:  2006-03       Impact factor: 2.037

4.  Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart.

Authors:  Nihal Ozturk; Nazmi Yaras; Asli Ozmen; Semir Ozdemir
Journal:  J Bioenerg Biomembr       Date:  2013-05-03       Impact factor: 2.945

5.  Acute simvastatin inhibits K ATP channels of porcine coronary artery myocytes.

Authors:  Sai Wang Seto; Alice Lai Shan Au; Christina Chui Wa Poon; Qian Zhang; Rachel Wai Sum Li; John Hok Keung Yeung; Siu Kai Kong; Sai Ming Ngai; Song Wan; Ho Pui Ho; Simon Ming Yuen Lee; Maggie Pui Man Hoi; Shun Wan Chan; George Pak Heng Leung; Yiu Wa Kwan
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

6.  The AMP-Dependent Protein Kinase (AMPK) Activator A-769662 Causes Arterial Relaxation by Reducing Cytosolic Free Calcium Independently of an Increase in AMPK Phosphorylation.

Authors:  Yi Huang; Corey A Smith; Grace Chen; Bharti Sharma; Amy S Miner; Robert W Barbee; Paul H Ratz
Journal:  Front Pharmacol       Date:  2017-10-18       Impact factor: 5.810

7.  Repurposing simvastatin as a therapy for preterm labor: evidence from preclinical models.

Authors:  Ashley K Boyle; Sara F Rinaldi; Adriano G Rossi; Philippa T K Saunders; Jane E Norman
Journal:  FASEB J       Date:  2018-10-12       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.